Serum GGT levels have been reported as a poor prognostic factor in breast cancer [19], esophagus cancer [20], cervical cancer [21], kidney cancer [22], ovarian cancer [23], stomach cancer [24], nonsmall lung cancer (NSCLC) [10], and colorectal cancer [11]. This evidence concerns the gene GGT1 and ovarian cancer.